Because CX-2009 is not cross-reactive with mouse CD166, tumor uptake in this case depends on antigen expression in the tumor, antibody dose, and the protease activity that leads to a removal of the masking peptide in the tumor microenvironment. Here, ALCAM is linked to neoplasm.